Experimental combo therapy targets deadly brain cancer
NCT ID NCT03491683
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times
Summary
This early-stage trial tested a DNA-based vaccine (INO-5401 and INO-9012) combined with an immunotherapy drug (cemiplimab) plus standard radiation and chemotherapy in 52 people with newly diagnosed glioblastoma, an aggressive brain cancer. The goal was to see if the combination is safe and helps the immune system fight the tumor. Participants had to be in relatively good health and on low doses of steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
City of Hope
Duarte, California, 91010, United States
-
Columbia University Medical Center The Neurological Institute of New York
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
New York University Langone Medical Center; Perlmutter Cancer Center
New York, New York, 10016, United States
-
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Rutgers University - Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
Stanford University, School of Medicine
Palo Alto, California, 94304, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Texas Oncology
Austin, Texas, 78705, United States
-
UPMC Cancer Center Neuro-Oncology; UPMC Cancer Pavilion
Pittsburgh, Pennsylvania, 15232, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of North Carolina School of Medicine
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania Health System: Penn Medicine
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.